Author of

• 30601

  +

  P2.01 - Advanced NSCLC (ID 159)

  • Event: WCLC 2019
  • Type: Poster Viewing in the Exhibit Hall
  • Track: Advanced NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall

  • 30638

    +

    P2.01-37 - Lower Risk of Hypercoagulability in Non-Small Cell Lung Cancer Patients with EGFR Mutations (ID 1602)

    10:15 - 18:15  |  Author(s): Kenichi Suda
    • Abstract

    Background
    

    Hypercoagulability is sometimes observed in cancer patients, including non-small cell lung cancer (NSCLC) patients. Plasma levels of fibrinogen or D-dimer are used as markers for hypercoagulability, and several previous studies have reported that upregulation of these markers are poor prognostic factors in NSCLCs. On the other hand, recent studies have highlighted clinical differences between NSCLCs with EGFR mutation and those without. However, there is no data about the difference in hypercoagulability between NSCLCs with EGFR mutation and those without.

    Method
    

    Between January 2007 to December 2016, 270 surgically resected NSCLC patients received EGFR mutation testing and were included in this study. Plasma fibrinogen and D-dimer levels were examined as one of pre-surgical examinations in all patients. We analyzed the correlation between plasma fibrinogen / D-dimer levels and EGFR mutation status.

    Result
    

    Among 270 patients in our cohort, 123 patients had EGFR mutation and 147 patients were wild type (WT) for the EGFR. In our cohort, plasma fibrinogen level was upregulated in 39 patients, while plasma D-dimer level was upregulated in 75 patients. Plasma fibrinogen was upregulated in 9 patients (7%) and in 30 patients (20%) in EGFR mutation group and in WT EGFR group, respectively (p = 0.0017). Plasma D-dimer was upregulated in 27 patients (22%) and in 48 patients (33%) in EGFR mutation group and in WT EGFR group, respectively (p = 0.049). These correlations were still significant after the adjustment with clinical factors including smoking status, age, and histology. In multivariate analysis, odds ratio and 95% CI in EGFR mutation group for upregulated plasma fibrinogen were 0.40 and 0.17 – 0.94, respectively (p = 0.037). On the other hand, odds ratio and 95% CI in EGFR mutation group for upregulated plasma D-dimer were 0.48 and 0.26 – 0.90, respectively (p = 0.022).

    Conclusion
    

    Plasma levels of fibrinogen and D-dimer were significantly lower in NSCLCs with EGFR mutation.